COMPANY PROFILE
Pharmact is an innovative biopharmaceutical company specialising in the development of novel therapeutic agents for the treatment of atherosclerosis, arteriosclerosis, and related conditions.
As a holding structure, Pharmact Holding AG coordinates specialised subsidiaries handling research, clinical development, production, and commercialisation of its proprietary therapeutic platform.
Pharmact holds a robust portfolio of patents, trademarks, and utility models across key global markets, including Europe and the US.
Its German base in Saarlouis manages regulatory and operational functions, while its Florida presence is dedicated to securing FDA approval.
Since its establishment in Berlin in 2014, the company has been fully supported by private investors and shareholders.
STRATEGY
Innovative Therapeutic Platform Targeting Atherosclerosis
Based on years of research and extensive compassionate-use cases, we have developed a biotechnological enzyme (drug candidate) designed to directly reduce or eliminate the root causes of serious vascular conditions. Initial therapeutic applications using limited animal-derived material have already demonstrated the efficacy of our innovative approach to treating atherosclerosis.
Pharmact has achieved functional validation of the engineered enzyme through preclinical trials conducted by Charles River Laboratories (USA). The studies were performed on genetically modified mice with severe hyperlipidaemia. The successful proof-of-concept has been fully documented and serves as the foundation for the next regulatory steps.
Regulatory approval will proceed via structured clinical trials. The first study cohorts will include adults and adolescents with heterozygous familial hypercholesterolaemia (heFH) and diagnosed atherosclerosis. Based on trial outcomes, the treatment will be extended to paediatric patients suffering from the rare homozygous form of the condition (hoFH).
Pharmact is supported by experienced clinicians, specialised service providers, and strategic partners across all areas of business development. Each project phase is subject to critical evaluation and validation by independent auditors to ensure commercial and strategic viability.
INVEST IN THE FUTURE OF HEALTHCARE
With BELACT, Pharmact is pursuing a biotechnological solution for the treatment of the rare condition familial hypercholesterolaemia, as well as atherosclerosis and arteriosclerosis—widespread diseases with substantial societal and economic burden.
Pharmact represents a clearly defined therapeutic approach with disruptive potential, protected intellectual property, and access to a rapidly growing target market.
To realize our next key milestones—Phases I, II, and III of clinical development—we are seeking strategic partners committed to innovation, medical progress, and public health impact.
We offer strategic investors a range of forward-looking opportunities, including licensing to pharmaceutical partners, a potential M&A transaction following clinical validation, broad application across other vascular indications, and the build-out of long-term commercialisation channels.
Click „Investor“ to get in touch.